page-2.html
Novo Annual Report 2015
3 / 72
contents 04 the
novo
group 05 novo a/s 06 2015
in brief 07 letter from the chairman 08 board of directors and management 10 management report 16 large investments 17 investing in mature life science companies
18 xellia 19 sonion 20 chr. hansen 21 symphogen and orexo 22 veloxis and inogen 23 btg 24 ventures 25 a unique approach to venture investments 26 m&as and ipos in 2015 27 anatomy of an exit 28 introducing the class of 2015 29 portfolio company achievements in 2015 30 novo ventures opens a new office in boston 32 active portfolio companies in figures 34 private companies 36 public companies 37 selected exits 38 merus ? boosting natural antibodies 40 irhythm ? a silicon valley medical device company 42 seeds 43 investing in early-stage life science 44 active seed companies and pre-seed projects 45 novo seeds investments 2015 46 exit epitherapeutics 48 a seed investment in minervax 50 finance 51 continued performance above benchmarks 54 novo nordisk foundation and the novo group 55 novo nordisk fonden 56 novo nordisk a/s 57 novozymes a/s 58 nnit a/s 59 charter for companies in the novo group 60 novo?s cornerstones ? in our interactions 61 the team 64 csr in novo a/s 66 accounts, extracts annual review 2015 3 contents
share-novos-novo-4.html
